Clinical trials: Inhalation
Asthma
A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device
This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two different formulations of indacaterol maleate, both administered via the Concept1 device.
- Trial name
- NCT01484197
- Testing
- 75 µg indacaterol maleate (LB), 75 µg indacaterol maleate (PoS), 37.5 µg indacaterol maleate (PoS)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers
Evaluation of safety, tolerability and pharmacokinetics of single rising intravenous doses of BEA 2180 BR; additional exploration of metabolism following inhalation
- Trial name
- NCT02254720
- Testing
- BEA 2180 BR solution for infusion, BEA 2180 BR solution for inhalation, Respimat®
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113373 (NCT01313650)
- Testing
- 62.5/25mcg, 62.5mcg, 25mcg
- Where
- 165 sites in United States, Bulgaria and 11 more
- Volunteers
- 1,538 people
- Sponsor
- GlaxoSmithKline
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140320
- Testing
- RV1729 single dose, RV1729 14 day repeat dose, RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Cystic Fibrosis
Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients
Cystic Fibrosis (CF) is the most common autosomal recessive lethal disorders affecting 1:2.500 newborns among Caucasians. CF patients are peculiarly susceptible to infection and colonization of the respiratory tract with…
- Trial name
- NCT04176328
- Testing
- Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Neupharma Srl
Asthma
To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
A Phase 1 study to assess pharmacokinetics (PK) and safety of abediterol 5 μg dry powder inhaler (DPI) given once daily (QD) for 9 days, compared to placebo, in patients with asthma on inhaled corticosteroids (ICSs).
- Trial name
- NCT03273127
- Testing
- Abediterol
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
This study is a phase III clinical study to assess the efficacy and safety of Revefenacin inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to placebo in a population of Chinese subjects…
- Trial name
- NCT05046795
- Testing
- Revefenacin 175 mcg in 3 ML Inhalation Solution
- Where
- 35 sites in China
- Volunteers
- 258 people
- Sponsor
- Mylan Pharma UK Ltd.
High Altitude Pulmonary Hypertension
Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis.
- Trial name
- HAPE (NCT06852924)
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Novlead Inc.
Asthma
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ARO-RAGE in normal healthy volunteers (NHVs) and in participants with inflammatory lung disease (asthma).
- Trial name
- NCT05276570
- Testing
- ARO-RAGE
- Where
- 8 sites in Australia, New Zealand and 3 more
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Healthy, Healthy Smoker
Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease
This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.
- Conditions
- Healthy, Healthy Smoker, COPD (Chronic Obstructive Pulmonary Disease), COPD
- Trial name
- NCT07285122
- Testing
- RB042
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Atisama Therapeutics
Pulmonary Disease, Chronic Obstructive
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00932646
- Testing
- BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Foradil
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.
- Conditions
- Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis
- Trial name
- NCT05897294
- Testing
- Voriconazole Inhalation Powder
- Sponsor
- TFF Pharmaceuticals, Inc.
Asthma
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
This is an observational retrospective analysis of linked pharmacy and medical claims data from IMS Health/Pharmetrics database.
- Trial name
- NCT01431924
- Testing
- Higher-dose inhaled corticosteroids, Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
- Volunteers
- 7,779 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in…
- Trial name
- NCT04150341
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Theravance Biopharma
Respiratory Failure
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation
This study aims to test direct application of the Non-Invasive Mechanical Ventilation -NIVM- mask or interface as the most efficient intervention to prevent Pressure Ulcers (PU), compared with other three usual preventive…
- Trial name
- PUPPVMNI (NCT02526862)
- Testing
- Allevyn Thin®, Askina Transorbent Border®, Linovera®
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- B. Braun Medical SA
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
The primary purpose of this study is to determine the safety and tolerability of escalating doses of C16TR for inhalation in healthy participants.
- Trial name
- NCT06193031
- Testing
- C16TR, Tyvaso®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Asthma in Children
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
single center, double-blind, double-dummy, 2-way cross over study in asthmatic children already treated with inhaled corticosteroids
- Trial name
- NCT01658891
- Testing
- combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg, free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg
- Where
- Denmark
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174720
- Testing
- Ciclesonide (XRP1526)
- Where
- 11 sites in United States, Brazil and 9 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.